Search

Your search keyword '"Dutcher, Sarah K."' showing total 35 results

Search Constraints

Start Over You searched for: Author "Dutcher, Sarah K." Remove constraint Author: "Dutcher, Sarah K." Database Complementary Index Remove constraint Database: Complementary Index
35 results on '"Dutcher, Sarah K."'

Search Results

1. Validity of inpatient electronic health record‐based measures of oxygen‐related therapy in the United States: Lessons applicable for studying COVID‐19 endpoints.

2. Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States.

3. Switching patterns of immediate‐release forms of generic mixed amphetamine salts products among privately and publicly insured individuals aged 15–64 years in the United States, 2013–2019.

4. Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation.

5. Treatment and care received by children hospitalized with COVID-19 in a large hospital network in the United States, February 2020 to September 2021.

6. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients.

7. Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data.

8. Validation of diagnosis codes to identify hospitalized COVID‐19 patients in health care claims data.

9. Using inpatient electronic medical records to study influenza for pandemic preparedness.

10. Uptake and Competition Among Biosimilar Biological Products in the US Medicare Fee-for-Service Population.

11. Validation of an electronic algorithm for Hodgkin and non‐Hodgkin lymphoma in ICD‐10‐CM.

12. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.

13. Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients.

14. Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study.

16. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.

17. Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use.

18. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.

19. A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications.

20. Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs.

21. COVID-19 vs Influenza for Risk of Thrombotic Events in Hospitalized Patients—Reply.

23. Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices.

24. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.

27. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.

28. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.

30. Effect of Medications on Physical Function and Cognition in Nursing Home Residents with Dementia.

31. Pharmacotherapeutic Management of Dementia Across Settings of Care.

34. Erratum. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90-97.

35. Correction to: Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence.

Catalog

Books, media, physical & digital resources